Cohance Lifesciences Names Umang Vohra as Executive Chairman & Group CEO

Umang Vohra brings more than three decades of experience in the pharmaceutical sector, most notably as CEO and Managing Director of Cipla, where he oversaw a transformation into a diversified global player.

Telangana-based Cohance Lifesciences, a tech-driven global CDMO platform, has announced the appointment of Umang Vohra as Executive Chairman from May 1, 2026, and Group CEO from May 20, 2026, positioning the company for its next phase of expansion and innovation.

The transition follows the resignation of Vivek Sharma as Executive Chairman and Director, who will step down at the end of April due to personal reasons, but will remain associated as a Special Advisor for nine months to ensure continuity.

Umang Vohra brings more than three decades of experience in the pharmaceutical sector, most notably as CEO and Managing Director of Cipla, where he oversaw a transformation into a diversified global player with a strong focus on innovation, speciality products, and emerging markets.

Commenting on his new role, Vohra said, “I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance's technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation.”

Backing this leadership transition, the company’s board has also approved a new employee stock option plan aligned with Securities and Exchange Board of India regulations.

The scheme includes over 25.9 Mn options, translating to 6.25% of the fully diluted equity base, with an exercise price set at not less than INR 325 per share. The structure includes a vesting period ranging from one to eight years.

Cohance Lifesciences, formerly known as Suven Pharmaceuticals, has built a specialised position in complex chemistry-driven manufacturing, including APIs, antibody-drug conjugates, oligonucleotides, and speciality ingredients. With over 400 scientists and an integrated R&D infrastructure, the company has established partnerships with global pharmaceutical innovators.

Stay tuned for more such updates on Digital Health News